BioNTech

Founded in Mainz, Germany, in 2008 by Özlem Türeci and Uğur Şahin, BioNTech SE emerged as a German multinational biotechnology firm dedicated to developing immunotherapies and vaccines for cancer and infectious diseases. The company built its reputation on a proprietary mRNA platform technology that allows it to engineer targeted therapies with speed and precision. While the organization operates globally, its roots remain firmly planted in the Rhine-Main region where it continues to drive research and development from its headquarters.

The world took notice when BioNTech partnered with Pfizer to co-develop Comirnaty (BNT162b2), the first approved mRNA-based COVID-19 vaccine. This collaboration became a cornerstone of global pandemic response efforts, generating significant revenue and brand recognition for the young firm. That success did not mark an end point but rather a transition phase as the company pivoted its long-term strategy toward oncology, aiming to harness the immune system's power to fight cancer through combination approaches and novel investigational therapies.

Recent years have seen aggressive financial moves and clinical challenges shape the narrative around the company. In November 2026, BioNTech paid $205 million to acquire an expedited FDA review voucher from Scholar Rock to accelerate regulatory approval for its late-stage oncology pipeline. This purchase followed mixed results elsewhere; a Phase 3 trial for its antibody-drug conjugate showed only modest efficacy alongside cases of interstitial lung disease, leading management to view limited benefit in that specific asset. Despite facing legal setbacks like a 36-country injunction secured by GSK against the Pfizer-BioNTech vaccine coalition in the Unified Patent Court, the company maintains a robust presence listed on NASDAQ under the ticker BNTX. [edit]